SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Shire plc – ‘10-K’ for 12/31/09 – ‘EX-21’

On:  Friday, 2/26/10, at 12:40pm ET   ·   For:  12/31/09   ·   Accession #:  950103-10-520   ·   File #:  0-29630

Previous ‘10-K’:  ‘10-K’ on 2/27/09 for 12/31/08   ·   Next:  ‘10-K’ on 2/23/11 for 12/31/10   ·   Latest:  ‘10-K’ on 2/20/18 for 12/31/17   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/10  Shire plc                         10-K       12/31/09   62:8.1M                                   Davis Polk & … LLP 01/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.87M 
 2: EX-10.26    Material Contract                                   HTML     37K 
 3: EX-21       Subsidiaries List                                   HTML     47K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
47: XML         IDEA XML File -- Definitions and References          XML    131K 
55: XML         IDEA XML File -- Filing Summary                      XML     94K 
52: XML.R1      Document And Entity Information                      XML     89K 
53: XML.R2      Consolidated Balance Sheets                          XML    268K 
32: XML.R3      Consolidated Balance Sheets (Parentheticals)         XML     57K 
37: XML.R4      Consolidated Balance Sheets (Parentheticals in       XML     33K 
                GBP)                                                             
45: XML.R5      Consolidated Statements of Operations                XML    365K 
44: XML.R6      Consolidated Statements of Operations                XML     51K 
                (Parentheticals)                                                 
59: XML.R7      Consolidated Statement of Changes in Shareholders'   XML   1.03M 
                Equity                                                           
22: XML.R8      Consolidated Statements of Comprehensive Income      XML    122K 
43: XML.R9      Components of Accumulated Other Comprehensive        XML     51K 
                Income                                                           
20: XML.R10     Consolidated Statements of Comprehensive Income      XML     59K 
                (Parentheticals)                                                 
19: XML.R11     Consolidated Statements of Cash Flows                XML    545K 
31: XML.R12     Description Of Operations                            XML     35K 
49: XML.R13     Summary Of Significant Accounting Policies           XML     80K 
33: XML.R14     Business combinations                                XML     79K 
34: XML.R15     Termination costs                                    XML     38K 
41: XML.R16     Gain on sale of product rights                       XML     35K 
62: XML.R17     Reorganization costs                                 XML     43K 
29: XML.R18     Intergration and Acquisition costs                   XML     35K 
15: XML.R19     Accounts receivable, net                             XML     38K 
36: XML.R20     Inventories                                          XML     37K 
48: XML.R21     Assets held for sale                                 XML     35K 
25: XML.R22     Prepaid expenses and other current assets            XML     37K 
46: XML.R23     Investments                                          XML     40K 
35: XML.R24     Property Plant and Equipment, net                    XML     38K 
58: XML.R25     Goodwill                                             XML     39K 
51: XML.R26     Other intangible assets, net                         XML     43K 
38: XML.R27     Accounts payable and accrued expenses                XML     43K 
42: XML.R28     Other current liabilities                            XML     37K 
18: XML.R29     Long-term debt                                       XML     40K 
21: XML.R30     Other long-term debt                                 XML     36K 
26: XML.R31     Other non-current liabilities                        XML     37K 
30: XML.R32     Derivative instruments                               XML     45K 
40: XML.R33     Fair value measurement                               XML     53K 
50: XML.R34     Commitments and contingencies                        XML     56K 
17: XML.R35     Shareholders Equity                                  XML     41K 
23: XML.R36     Earnings per share                                   XML     52K 
54: XML.R37     Segmental reporting                                  XML     97K 
57: XML.R38     Interest expense                                     XML     36K 
39: XML.R39     Other income (expenses), net                         XML     39K 
60: XML.R40     Retirement benefits                                  XML     34K 
24: XML.R41     Taxation                                             XML     86K 
61: XML.R42     Share-based compensation plans                       XML     71K 
28: XML.R43     Restatement of previously issued financial           XML     35K 
                statements                                                       
16: XML.R44     Income Access Share Trust Financial Statements       XML     62K 
27: XML.R45     Valuation and Qualifying Accounts Schedule           XML     45K 
56: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    206K 
 9: EX-101.INS  XBRL Instance -- shpgf-20091231                      XML    826K 
11: EX-101.CAL  XBRL Calculations -- shpgf-20091231_cal              XML    203K 
12: EX-101.DEF  XBRL Definitions -- shpgf-20091231_def               XML     86K 
13: EX-101.LAB  XBRL Labels -- shpgf-20091231_lab                    XML    822K 
14: EX-101.PRE  XBRL Presentations -- shpgf-20091231_pre             XML    468K 
10: EX-101.SCH  XBRL Schema -- shpgf-20091231                        XSD     99K 


‘EX-21’   —   Subsidiaries List


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

EXHIBIT 21
LIST OF SUBSIDIARIES
 
 
Subsidiary/undertaking
Jurisdiction of incorporation
 
     
3829359 Canada Inc.
Canada
 
Monmouth Pharmaceuticals Limited
United Kingdom
 
Pharma International Insurance Limited
Ireland
 
Rybar Laboratories Limited
United Kingdom
 
Shire 2005 Investments Limited
Cayman Islands
 
Shire Acquisition Inc
Canada
 
Shire Australia Pty Limited
Australia
 
Shire Belgium BVBA
Belgium
 
Shire Biopharmaceuticals Holdings
United Kingdom
 
Shire Biopharmaceuticals Ireland Limited
Ireland
 
Shire Biopharmaceuticals Ireland No.2 Limited
Ireland
 
Shire Canada Inc.
Canada
 
Shire Deutschland GmbH
Germany
 
Shire Deutschland Investments GmbH
Germany
 
Shire Development Inc
United States
 
Shire Europe Finance
United Kingdom
 
Shire Europe Limited
United Kingdom
 
Shire Executive Services LLC
United States
 
Shire Finance Limited
Cayman Islands
 
Shire France S.A.
France
 
Shire Global Finance
United Kingdom
 
Shire Hellas Pharmaceuticals Import Export and Marketing S.A.
Greece
 
Shire Holdings AG
Switzerland
 
Shire Holdings Europe B.V.
Netherlands
 
Shire Holdings Europe Limited
United Kingdom
 
Shire Holdings Europe No.2 S.a.r.l.
Luxembourg
 
Shire Holdings Ireland Limited
Ireland
 
Shire Holdings Ireland No.2 Limited
Ireland
 
Shire Holdings Limited
Bermuda
 
Shire Holdings UK Canada Limited
United Kingdom
 
Shire Holdings UK Limited
United Kingdom
 
Shire Holdings US AG
United States
 
Shire Human Genetic Therapies (Canada) Inc.
Canada
 
Shire Human Genetic Therapies AB
Sweden
 
Shire Human Genetic Therapies SA
Argentina
 
Shire Human Genetic Therapies Inc
United States
 
Shire Human Genetic Therapies Limited
United Kingdom
 
Shire Human Genetic Therapies Farmaceutica Ltda
Brazil
 
Shire Human Genetic Therapies Securities Corporation
United States
 
Shire Human Genetic Therapies UK Limited
United Kingdom
 
Shire Incorporated
United States
 
Shire Intellectual Property 2 SRL
Barbados
 
Shire Intellectual Property Ireland Limited
Ireland
 
Shire Intellectual Property SRL
Barbados
 
Shire International Licensing BV
Netherlands
 
Shire Investments & Finance (U.K.) Company
United Kingdom
 
Shire IP Services Corporation
Canada
 
Shire Italia S.p.A.
Italy
 
Shire Jersey Limited
Jersey
 
Shire LLC
United States
 
Shire Luxembourg Intellectual Property No.2 S.a r.l.
Luxembourg
 
Shire Luxembourg Intellectual Property S.a r.l.
Luxembourg
 
Shire Luxembourg Sarl
Luxembourg
 
Shire Pharmaceutical Contracts Limited
United Kingdom
 
Shire Pharmaceutical Development Inc
United States
 
 
 

 
 
Shire Pharmaceutical Development Limited
United Kingdom
 
Shire Pharmaceutical Holdings Ireland Limited
Ireland
 
Shire Pharmaceutical Investment Holdings Limited
Malta
 
Shire Pharmaceutical Investment Limited
Malta
 
Shire Pharmaceutical Investment Trading Ireland
Ireland
 
Shire Pharmaceutical Investments 2008
Ireland
 
Shire Pharmaceuticals Group
United Kingdom
 
Shire Pharmaceuticals Iberica S.L.
Spain
 
Shire Pharmaceuticals Inc
United States
 
Shire Pharmaceuticals Investments (British Virgin Islands) Limited
Virgin Islands, British
 
Shire Pharmaceuticals Investments 2007
Ireland
 
Shire Pharmaceuticals Ireland Limited
Ireland
 
Shire Pharmaceuticals Limited
United Kingdom
 
Shire Pharmaceuticals Mexico SA de CV
Mexico
 
Shire Pharmaceuticals Services Limited
United Kingdom
 
Shire Properties US
United States
 
Shire Regulatory Inc
United States
 
Shire Supplies U.S. LLC
United States
 
Shire UK Investments Limited
United Kingdom
 
Shire US Holdings Inc.
United States
 
Shire US Inc
United States
 
Shire US Investments
United Kingdom
 
Shire US Manufacturing Inc
United States
 
Sparkleflame Limited
United Kingdom
 
Tanaud International BV
Netherlands
 
Tanaud Ireland Inc.
Ireland
 
The Endocrine Centre Limited
United Kingdom
 
TKT Argentina srl
Argentina
 
Jerini AG
Germany
 
Jerini US, Inc.
United States
 
JPT Peptide Technologies, Inc.
United States
 
Jerini Ophthalmic Holding GmbH
Germany
 
Jerini Ophthalmic, Inc.
United States
 
Jerini Beteiligungen GmbH
Germany
 
Jerini Holding Limited
Malta
 
Jerini Trading Limited
Malta
 

 
 
 


 

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/25/10  SEC                               UPLOAD9/11/17    1:21K  Shire plc
 4/14/10  SEC                               UPLOAD9/11/17    1:31K  Shire plc
Top
Filing Submission 0000950103-10-000520   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 19, 6:17:41.1pm ET